Xeris Biopharma Holdings, Inc.
XERS
$5.48
-$0.25-4.36%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 15.36% | 3.97% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 15.36% | 3.97% | |||
| Cost of Revenue | -0.45% | -7.58% | |||
| Gross Profit | 18.11% | 6.28% | |||
| SG&A Expenses | 2.24% | 4.65% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.05% | 0.88% | |||
| Operating Income | 149.19% | 50.18% | |||
| Income Before Tax | 1,684.38% | 132.21% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 1,684.38% | 132.21% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 1,684.38% | 132.21% | |||
| EBIT | 149.19% | 50.18% | |||
| EBITDA | 102.65% | 30.09% | |||
| EPS Basic | 1,657.89% | 131.40% | |||
| Normalized Basic EPS | 1,637.50% | 131.58% | |||
| EPS Diluted | 1,748.57% | 128.93% | |||
| Normalized Diluted EPS | 1,650.00% | 128.95% | |||
| Average Basic Shares Outstanding | 1.41% | 2.63% | |||
| Average Diluted Shares Outstanding | 1.38% | 11.39% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||